Close
Close
Cagrilintide

Cagrilintide 3-Month Membership Program

$900.00

4.9 Avg. Rating

1000+ Reviews

  • Follow-up Exam
  • Lab Review
  • Dose Adjustments
  • Certificate of Authenticity
  • 503A Pharmacies
  • 99% Pure
  • US-based Peptides
Cagrilintide is a medication that comes up in conversations about weight management, often alongside a related combination product called CagriSema. Because there’s considerable online interest, and some understandable confusion, about whether Cagrilintide is available today, this page is meant to give you a clear, honest picture of what it is and where things currently stand.
Cagrilintide is an investigational medication being developed by a pharmaceutical company. It’s a long-acting version of a natural hormone called amylin, which your body normally produces alongside insulin and which plays a role in feelings of fullness and how quickly your stomach empties after eating. Cagrilintide has been studied both on its own and in combination with another hormone-based medication, semaglutide, as part of a combination product called CagriSema, which has shown substantial weight loss results in clinical trials.
Here is the most important thing for patients to understand: Cagrilintide has not been approved by the FDA, and it cannot currently be legally prescribed, dispensed, or compounded for use outside of a registered clinical trial. This is different from many other peptides discussed in wellness settings, which may exist in a more uncertain regulatory gray area. Cagrilintide’s situation is more clear-cut: it is an actively patented, in-development pharmaceutical product still completing the formal FDA review process, and no legal pathway currently exists for a telehealth practice, compounding pharmacy, or online vendor to provide it outside of that process.
We’re including this page because patients deserve honest, accurate information, even when the honest answer is “not yet available.” SevenHealth does not offer Cagrilintide, and we want to be transparent about why, while also pointing you toward options that are legally available and medically appropriate today.
To understand how Cagrilintide is designed to work, picture the hormone amylin as one part of a larger fullness-and-appetite signaling system in your body. Amylin is normally released alongside insulin after eating, and it helps signal fullness and slows down how quickly food moves through your stomach. Cagrilintide is designed to be a long-acting version of this natural hormone, engineered to stay active in the body longer than amylin normally would. This is a different hormone pathway than the one targeted by currently FDA-approved GLP-1 medications, which is part of why researchers have studied combining Cagrilintide with a GLP-1 medication, semaglutide, in the CagriSema combination product. The idea is that targeting both the amylin and GLP-1 pathways together might produce a bigger combined effect on appetite and weight than targeting either pathway alone. This dual-pathway approach is the reason for significant interest in Cagrilintide and CagriSema’s clinical trial results, but it’s also part of why the FDA review process takes the time it does, carefully evaluating how these combined hormone pathways behave together, over extended periods, across large and diverse patient populations.
  • Has shown substantial weight loss in clinical trial data, particularly as part of the CagriSema combination, with study participants losing meaningful percentages of body weight over extended treatment periods
  • Is currently being studied for its potential role in supporting metabolic health markers in ongoing trials, including in people with type 2 diabetes
  • May offer an enhanced effect when combined with a GLP-1 medication, based on trial data showing greater weight loss with the combination compared to either component alone
Because Cagrilintide remains investigational, these findings come specifically from controlled clinical trial settings, supervised by dedicated research teams, and do not reflect what would happen with unsupervised, unregulated use outside of that setting.
Because Cagrilintide is not currently available for prescription outside of clinical trials, this section looks a little different than on our other peptide pages. Patients who are curious about Cagrilintide are often the same patients who would benefit from a conversation about:
  • Weight management support using currently FDA-approved medications, which SevenHealth does offer as part of our GLP-1 Medical Weight Loss program
  • Metabolic health optimization, for patients interested in blood sugar and related markers
  • Enrollment in a registered clinical trial, for patients who want access to Cagrilintide or CagriSema specifically and meet the eligibility criteria, which can be explored through public clinical trial registries
We encourage any patient interested in Cagrilintide to have an honest conversation with a licensed provider about currently available, FDA-approved options that can address similar goals today.
Cagrilintide has been studied in large clinical trials, both as a standalone medication and, more prominently, as part of the CagriSema combination product alongside semaglutide. In pivotal trials, participants receiving the combination lost substantially more weight on average than those receiving semaglutide alone, with study data showing meaningful improvements over an extended treatment period compared to both placebo and single-medication comparison groups. It’s important to be transparent that despite these promising results, the manufacturer’s application for FDA approval of the CagriSema combination was still under formal review as of the most recent public updates, with an agency decision expected sometime in 2026 or later, depending on the review timeline. Standalone Cagrilintide approval, if it happens, would likely follow the combination product’s review by a considerable additional stretch of time. Because of the gap between promising trial data and formal approval, patients should be aware that Cagrilintide currently sits in a regulatory position where it is neither approved nor available through any legal compounding or prescribing pathway in the United States. Some individuals and businesses have nonetheless offered similar-sounding products outside this legal framework, which carries both legal and safety risks. SevenHealth does not participate in this practice.
Because Cagrilintide remains in clinical trials, its full safety profile, including any rare or long-term effects, is still being characterized through the formal research process. Reported effects in trials to date have generally included digestive symptoms such as nausea, which are common with this category of medication and often improve over time, consistent with related approved medications that work on similar or overlapping pathways. Products sold outside of registered clinical trials as “Cagrilintide,” whether online or through unauthorized clinics, are not subject to the same manufacturing, purity, and safety oversight as medications going through the FDA review process. This means their actual content, purity, and safety cannot be verified, which is a meaningful and separate risk from the medication’s own studied safety profile. Because Cagrilintide is not legally available outside of clinical trials, the most important safety consideration for interested patients is working with a licensed provider on currently approved options, or exploring legitimate clinical trial enrollment through recognized research institutions.

What is Cagrilintide?

It’s an investigational, long-acting version of the natural hormone amylin, studied for its role in appetite regulation and weight management, both alone and combined with semaglutide as CagriSema.

Is Cagrilintide FDA-approved?

No. As of now, neither Cagrilintide nor the CagriSema combination has received final FDA approval, and Cagrilintide cannot be legally prescribed, dispensed, or compounded outside of a registered clinical trial.

Can I get Cagrilintide through SevenHealth?

No. SevenHealth does not offer Cagrilintide, since it is not legally available for prescription outside of clinical trials. We’re happy to discuss FDA-approved weight management options that are available today.

How can I access Cagrilintide?

The only legal way to access Cagrilintide currently is through enrollment in a registered clinical trial, which can be explored through public clinical trial registries.

Is it safe to buy Cagrilintide online?

We strongly advise against this. Products sold outside the clinical trial process are not verified for content, purity, or safety, and providing or purchasing Cagrilintide outside of a clinical trial is not a legal pathway.

When will Cagrilintide be available by prescription?

The CagriSema combination product’s FDA application was under review as of the most recent public updates, with a decision possible in 2026 or later. Standalone Cagrilintide approval would likely take additional time beyond that.

What are the current FDA-approved alternatives?

SevenHealth offers several FDA-approved GLP-1 medications for weight management. Your provider can discuss which option may be appropriate for your specific health history and goals.

Is a consultation required to discuss weight management?

Yes. A telehealth consultation with a licensed medical provider is required to discuss FDA-approved weight management options at SevenHealth.

Will SevenHealth offer Cagrilintide once it’s approved?

If Cagrilintide or CagriSema receives FDA approval, we will evaluate the full evidence base and safety data before determining whether to offer it as part of our treatment programs.

Can I be notified when Cagrilintide becomes available?

Speak with our team about staying informed on FDA-approved weight management options as they become available.
  • Cagrilintide is an investigational, long-acting amylin analog studied for weight management, both alone and combined with semaglutide as CagriSema.
  • Clinical trial data for the CagriSema combination has shown greater weight loss than semaglutide alone.
  • Cagrilintide has not received FDA approval and cannot be legally prescribed, dispensed, or compounded outside of a registered clinical trial.
  • SevenHealth does not offer Cagrilintide, given its current legal and regulatory status.
  • Products sold as “Cagrilintide” outside clinical trials are not verified for safety, purity, or authenticity.
  • Patients interested in Cagrilintide’s benefits today can discuss FDA-approved weight management options through SevenHealth’s GLP-1 program.
  • The CagriSema combination’s FDA decision timeline extends into 2026 or later; standalone approval would likely take longer.
  • We encourage patients to be cautious of any provider offering Cagrilintide for purchase or prescription outside of clinical trials.

Educational Disclaimer

This information is provided for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Peptide therapy should only be used under the supervision of a licensed healthcare provider after an appropriate medical evaluation. Individual results may vary.

$100 OFF GLP-1 Injectable Plans for New Members ! CODE: